PXD066812 is an
original dataset announced via ProteomeXchange.
Dataset Summary
| Title | Shifting Beyond Classical Drug Synergy in Combinatorial Therapy through Solubility Alterations |
| Description | Acute myeloid leukemia (AML) poses a major clinical challenge due to its genetic diversity, relapse rates, and chemotherapy toxicity. While rational drug combinations improve efficacy, their mechanisms remain poorly understood. We introduce CoPISA (Proteome Integral Solubility/Stability Alteration Analysis for Combinations), a high-throughput proteomics workflow that identifies protein solubility/stability changes unique to drug combinations. Applied to two AML drug pairs—LY3009120-sapanisertib (LS) and ruxolitinib-ulixertinib (RU)—CoPISA mapped protein targets in lysates and living cells. The analysis revealed a novel principle, “conjunctional targeting”, where drug pairs induce unique, cooperative effects not seen with individual drugs, akin to an AND-gate logic. LS-specific targets involved SUMOylation, chromatin condensation, and VEGF-linked adhesion; RU-specific targets disrupted DNA damage checkpoints, mitochondrial function, and RNA splicing, suggesting synthetic-lethal vulnerabilities. Post-translational modification profiling confirmed combination-induced changes (e.g., acetylation, dimethylation, phosphorylation) on key AML proteins like NPM1. Network analysis showed many targets were unique to combinations, including frequently mutated drivers DNMT3A, NPM1, and TP53. CoPISA reveals how drug pairs exert multi-axis pressure on AML cells, offering a mechanistic layer beyond classical synergy and guiding precision therapy design for AML and other complex cancers. |
| HostingRepository | PRIDE |
| AnnounceDate | 2026-02-12 |
| AnnouncementXML | Submission_2026-02-12_09:23:47.500.xml |
| DigitalObjectIdentifier | |
| ReviewLevel | Peer-reviewed dataset |
| DatasetOrigin | Original dataset |
| RepositorySupport | Unsupported dataset by repository |
| PrimarySubmitter | Uladzislau Vadadokhau |
| SpeciesList | scientific name: Homo sapiens (Human); NCBI TaxID: NEWT:9606; |
| ModificationList | asymmetric dimethyl-L-arginine; phosphorylated residue; acetylated residue; iodoacetamide derivatized residue |
| Instrument | Orbitrap Eclipse |
Dataset History
| Revision | Datetime | Status | ChangeLog Entry |
|---|
| 0 | 2025-07-31 10:14:27 | ID requested | |
| ⏵ 1 | 2026-02-12 09:23:48 | announced | |
Publication List
Keyword List
| submitter keyword: combination therapy,Acute myeloid leukaemia, Proteome Integral Solubility Alteration assay for combinations, CoPISA |
Contact List
| Mohieddin Jafari |
|---|
| contact affiliation | Systems Pharmacology lab, Department of Biochemistry and Developmental Biology, Faculty of Medicine, University of Helsinki, Finland |
| contact email | mohieddin.jafari@helsinki.fi |
| lab head | |
| Uladzislau Vadadokhau |
|---|
| contact affiliation | University of Helsinki |
| contact email | uladzislau.vadadokhau@helsinki.fi |
| dataset submitter | |
Full Dataset Link List
Dataset FTP location
NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/02/PXD066812 |
| PRIDE project URI |
Repository Record List
[ + ]
[ - ]
- PRIDE
- PXD066812
- Label: PRIDE project
- Name: Shifting Beyond Classical Drug Synergy in Combinatorial Therapy through Solubility Alterations
